Should we use the oral selective IP receptor agonist selexipag off-label in children with pulmonary arterial hypertension?

Martin Koestenberger; Georg Hansmann

doi:10.1177/2045894018793580

Should we use the oral selective IP receptor agonist selexipag off-label in children with pulmonary arterial hypertension?

Pulm Circ. 2018 Jul-Sep;8(3):2045894018793580. doi: 10.1177/2045894018793580.

Authors

Martin Koestenberger¹, Georg Hansmann²

Affiliations

¹ 1 Division of Pediatric Cardiology, Department of Pediatrics, Medical University of Graz, Austria.
² 2 Department of Pediatric Cardiology and Critical Care, Hannover Medical School, Germany.

Abstract

We discuss the currently available data on the use of the prostacyclin mimetic selexipag in children and adolescents with pulmonary arterial hypertension (PAH). Future indications may include transitioning from intravenous prostacyclin/prostacyclin analog to oral selexipag, and vice versa, or adding selexipag as a third oral PAH-targeted agent in children not responding well to dual PAH therapy.

Keywords: Pediatric; prostacyclin receptor agonist; pulmonary arterial hypertension; selexipag.